Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study
Journal of the National Comprehensive Cancer Network · 2025
DOI: 10.6004/jnccn.2024.7093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2025. Verfasst von Caroline Boman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) for early-stage breast cancer is prognostic, but not the sole surrogate marker for long-term outcome at a trial level, given that recurrence risk persists in patients who achieve pCR. This study aimed to investigate factors affecting the outcome of patients who achieve pCR.
Methods
This population-based cohort study prospectively enrolled patients who received NACT for nonmetastatic breast cancer between 2007 and 2020 in the Stockholm-Gotland region, which comprises 25% of the entire Swedish population. The primary endpoint was distant relapse-free survival (DRFS), defined as time from surgery to distant recurrence or death from any cause.
Results
Median follow-up from surgery was 5.9 years. Among 2,487 patients, 661 (26.6%) attained pCR. Several factors were independently associated with DRFS in patients with pCR, including increasing age (adjusted hazard ratio [aHR], 1.04; 95% CI, 1.01–1.06), T3/T4 stage (aHR, 2.02; 95% CI, 1.05–3.87), and HER2 positivity (aHR, 0.34; 95% CI, 0.17–0.68). Node positivity predicted distant recurrence during the first year postsurgery (aHR, 2.84; 95% CI, 1.16–6.94), whereas estrogen receptor positivity predicted distant recurrence at 5 to 10 years (aHR, 4.30; 95% CI, 1.06–17.49). The rate of central nervous system relapse as the first site of recurrence was not affected by pCR status (5.3% vs 4.1%; P =.21).
Conclusions
In this population-based study, our findings suggest that patients achieving pCR after NACT are a heterogeneous group in terms of long-term prognosis. Baseline tumor characteristics should be considered when investigating post-neoadjuvant therapy approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden.
- Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
- Department of Surgery and Oncology, Capio Sankt Göran Hospital, Stockholm, Sweden.
Zitieren
APA
Boman, C., Tranchell, C., Liu, X., Eriksson Bergman, L., Toli, M. A., Bergh, J., Foukakis, T., & Matikas, A. (2025). Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2024.7093
Vancouver
Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, et al. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. Journal of the National Comprehensive Cancer Network. 2025. doi:10.6004/jnccn.2024.7093
BibTeX
@article{Boman2025,
author = {Boman, Caroline and Tranchell, Christian and Liu, Xingrong and Eriksson Bergman, Louise and Toli, Maria Angeliki and Bergh, Jonas and Foukakis, Theodoros and Matikas, Alexios},
title = {Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2025},
doi = {10.6004/jnccn.2024.7093}
}
EUVIMED